Aktiesnakken — Juni 2013
-
Sanofi opruster på diabetes-fronten
Franske Sanofi er godt på vej til at ruste sig til kampen om andele på det globale marked for diabetesmedicin. Og det indebærer bl.a. en samling af faciliteter, med tilnavnet Insulin City, hvor man udelukkende fokuserer på diabetesområdet.
(medwatch.dk)
-
er der nogen, der sidder med en hotline til Rachel?
-
Ja sukker det er super for Zealand. Sanofi har i den grad ikke opgivet LixiLan
-
To fend off its rivals, Sanofi is testing an improved version of Lantus in late-stage trials as well as a combination of the product with Lyxumia, a once-daily injection that controls blood sugar levels in a different way.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind